Efficacy of Avastin in combination with irinotecan for metastatic colorectal cancer.
- Author:
Hang ZHENG
1
;
Jin-zhang CHEN
;
Wang-jun LIAO
;
Rong-cheng LUO
Author Information
- Publication Type:Journal Article
- MeSH: Adenocarcinoma; drug therapy; pathology; Adult; Aged; Antibodies, Monoclonal; administration & dosage; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; therapeutic use; Bevacizumab; Camptothecin; administration & dosage; analogs & derivatives; Colorectal Neoplasms; drug therapy; pathology; Female; Fluorouracil; administration & dosage; Humans; Leucovorin; administration & dosage; Male; Middle Aged; Neoplasm Metastasis; Treatment Outcome
- From: Journal of Southern Medical University 2006;26(5):689-691
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the efficacy of Avastin in combination with irinotecan for metastatic colorectal cancer.
METHODSNinety patients were randomly divided into 3 equal groups to receive Avastin plus irinotecan (group A), FOLFIRI (group B) and FOLFOX7 (group C) for two cycles, respectively. The response rate and changes in tumor maker levels were observed.
RESULTSThe tumor response rate was 43.3% in group A, 27.7% in group B and 30.0% in group C. The disease control rate (complete response+partial response+stable disease) was 80% in group A, 53.3% in group B and 50.0% in group C. Obvious changes in tumor marker levels were observed in the 3 groups after treatment, which were most conspicuous in group A (P<0.05).
CONCLUSIONThe addition of Avastin to irinotecan chemotherapy results in significant improvement of clinical efficacy in patients with metastatic colorectal cancer.
